Research programme: Lysosomal storage disease therapeutics - bioOasis/Takeda
Latest Information Update: 06 May 2024
At a glance
- Originator Shire
- Developer biOasis Technologies; Shire
- Class Drug conjugates; Enzymes
- Mechanism of Action Biological transport stimulants; Enzyme replacements; Transferrin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lysosomal storage diseases